GLP-1 Drugs Show Promise in Preventing Post-Heart Attack Complications

Research indicates that GLP-1 weight-loss drugs, such as Ozempic and Wegovy, may assist individuals who have experienced a heart attack in preventing potentially fatal complications. The study suggests these drugs reduce tissue damage, a complication affecting up to 50% of the approximately 100,000 annual heart attack patients in the UK.

Experts in heart health concluded that GLP-1 drugs "could offer a promising new therapeutic approach for improving heart attack recovery."

While these drugs are known to lower the risk of heart attacks or strokes, this new research explores their potential to treat common post-heart attack complications, moving beyond their established benefits for weight loss and primary prevention.

Unveiling 'No-Reflow': A Critical Complication

Dr. Svetlana Mastitskaya, the study's lead author and a senior lecturer at Bristol University's medical school, explained that in nearly half of all heart attack patients, tiny blood vessels within the heart remain narrowed even after emergency treatment. This condition, known as 'no-reflow', prevents blood from reaching certain heart tissues.

No-reflow significantly increases the risk of mortality or hospital readmission for heart failure within a year of a heart attack. Dr. Mastitskaya noted that the findings suggest GLP-1 drugs may prevent this issue. She also stated that these drugs could potentially be administered by paramedics to heart attack patients, pending further clinical trials.

Next Steps: From Animal Models to Human Trials

However, the current results are derived from animal model trials, necessitating further human studies to confirm these benefits before GLP-1s can be used for this purpose in people. This crucial step will validate the findings and determine the safety and efficacy of these drugs in human patients post-heart attack.

The trial was funded by the British Heart Foundation and included experts from University College London. The results have been published in Nature Communications.

Prof. Bryan Williams, the BHF’s chief scientific and medical officer, commented that the study offers a possible explanation for how GLP-1 medicines produce heart health benefits beyond weight loss, suggesting they may improve blood flow through the heart’s smallest blood vessels.